Management of Elevated Normetanephrine and Total Metanephrines

Initial Assessment and Risk Stratification

The American College of Endocrinology recommends that patients with elevated normetanephrine and total metanephrines require alpha-adrenergic blockade as the primary medical treatment to prevent life-threatening cardiovascular complications, with the specific approach determined by the degree of elevation and presence of symptoms 1, 2, 3
Patients with normetanephrine levels ≥2-fold the upper reference limit should be considered for alpha-adrenergic blockade, especially if they have hyperadrenergic symptoms such as palpitations, tachycardia, diaphoresis, tremors, or new-onset hypertension 1, 2

The Endocrine Society recommends that alpha-adrenergic blockade is mandatory prior to any therapeutic intervention in patients with norepinephrine production, defined by elevated normetanephrine levels, to prevent life-threatening cardiovascular complications 1, 2, 3, 6
Phenoxybenzamine, a non-selective, non-competitive α1- and α2-blocker, should be started 7-14 days preoperatively with gradually increasing dosages until blood pressure targets are achieved, with a mean effective dosage of 140-270 mg/day 1, 7
Doxazosin, an α1-selective competitive blocker, is an alternative to phenoxybenzamine with similar efficacy for blood pressure control, and may cause less orthostatic hypotension 1, 8

Beta-adrenergic blockers should be added only after adequate alpha-blockade is established if tachycardia develops, and never used as monotherapy, as this can precipitate unopposed alpha-stimulation causing severe hypertension 1, 3, 6
Metyrosine, a tyrosine hydroxylase inhibitor, can be used as add-on therapy to reduce catecholamine biosynthesis by 35-80% 1, 3, 6

The American Heart Association recommends supportive measures to prevent perioperative complications, including a high-sodium diet, 1-2 liters IV saline 24 hours prior to surgery, and compression stockings to reduce orthostatic hypotension 7

Patients with dopamine-only producing tumors, characterized by isolated elevation of methoxytyramine, do not require alpha-adrenergic blockade prior to intervention, as they are typically normotensive or hypotensive 2, 3, 6

The National Comprehensive Cancer Network recommends that patients with confirmed pheochromocytoma/paraganglioma should undergo measurement of plasma/urine metanephrines 2-8 weeks postoperatively, imaging at 3-6 months post-treatment, and annual blood pressure measurements, clinical assessment, and biochemical testing lifelong 7
Whole-body MRI should be performed every 2-3 years to detect new tumors, metastases, or progression 7

The European Society of Endocrinology warns that never starting beta-blockers before alpha-blockade is the most critical error that can precipitate hypertensive crisis, and fine needle biopsy of suspected pheochromocytoma should be avoided due to risk of hypertensive crisis 1, 3, 5